Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investigative Press Flocks To EU Medtech Regulatory Conference: But Why?

Executive Summary

There were multiple investigative journalists with experience reporting on the "Paradise Papers," at the latest medtech regulatory conference in Brussels – but they gave nothing away about the medtech story they are pursuing.

You may also be interested in...

Device Sector Braces For Investigative Stories Critical Of Industry

AdvaMed has gotten wind over the past year that a major global investigative news consortium is planning to roll out a series of articles and broadcasts that are likely to be highly critical of the medical device industry. The group says it has been engaging with reporters in a push for balance.

Commissioner Says EU MDR/IVDR Implementation 'On Track,' But Fails To Convince Parliament

Elżbieta Bieńkowska, a European Commissioner,  is "realistic and confident" when it comes to the implementation of the new EU medtech regulations. She says everything is going to plan. But that is not what members of the European Parliament are hearing.

Top Medtech Lobbyist Doubts Legislative Repercussions Of New Netflix Documentary

AdvaMed's top lobbyist says a new documentary critical of the medical device industry and US FDA's device review pathways is unlikely to result in Congressional action. However, the group is talking to members on Capitol Hill to make sure they fully understand the context within which devices are reviewed and marketed.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts